Preclinical Validation

100% Tumor Eradication + Durable Immune Memory.

Viridion's lead candidate CARG-2020 has demonstrated proof-of-concept across multiple preclinical models, with results published in peer-reviewed scientific journals and reviewed in the first Pre-IND meeting with the FDA.

100%

Tumor eradication (treated cohort)

0%

Regrowth after rechallenge

4

Tumor types
validated

3

Peer-reviewed publications

Tumor Rechallenge Study

The Preclinical Signature of Recurrence Prevention.

In preclinical animal studies, CARG-2020 achieved 100% tumor eradication in the treated cohort. More importantly, treated animals resisted tumor re-implantation months after the original treatment course — demonstrating durable, systemic immune memory rather than localized tumor killing alone.

Tumor Rechallenge Results

Treated animals showed 0% regrowth after rechallenge; control animals showed 100% progression — the preclinical signature of recurrence prevention.

100%

Eradication in treated cohort

Alvero et al., 2023

A therapy that establishes lasting immune memory against recurrence is a fundamentally different category of medicine — and the basis for Viridion's clinical development strategy.

Cross-Tumor Activity

Validated Across Multiple Solid Tumor Models.

CARG-2020 has demonstrated anti-tumor activity across multiple preclinical models — without modification to the therapeutic construct.

Lead Indication

Ovarian Cancer

70% historical recurrence rate makes this the highest-priority clinical development population. Intraperitoneal delivery enables focused Phase I/Ib pathway.

Cross-Tumor

Melanoma

Cross-tumor immune memory confirmed in preclinical melanoma models — extending CARG-2020's relevance into immunotherapy-validated tumors.

High Unmet Need

Triple-Negative Breast Cancer

Breast cancer subtype with historically limited treatment options and significant unmet need. Preclinical efficacy demonstrated.

Independent Validation

Peer-Reviewed Publications.

Viridion's science has been published in peer-reviewed journals, providing independent validation of the platform and lead asset.

2023

Alvero et al.

Cancer Immunology Research — Tumor eradication and immune memory.

2024

Chen et al.

Acta Pharmaceutica Sinica B — Platform characterization and multi-payload expression.

2025

Ahmadi et al.

Scientific Reports — Mechanism validation and cross-tumor activity.

Regulatory

FDA Pre-IND Complete.

Viridion has completed its first Pre-IND meeting with the U.S. Food and Drug Administration. Outputs from the meeting informed the design of IND-enabling studies currently underway.

Pre-IND feedback received on GMP manufacturing standards and quality requirements for IND submission.

FDA input on GLP toxicology study design and nonclinical safety package for IND-enabling work.

Proposed Phase I/Ib trial design reviewed, including patient population, dose escalation, and biomarker strategy.

Potential eligibility for Orphan Drug and Breakthrough Therapy designations for recurrent ovarian cancer.

What's Next.

CARG-2020 is advancing through IND-enabling studies in preparation for Phase I/Ib trial in recurrent platinum-resistant ovarian cancer.

Or learn more about the AVIDIO™ platform